NCT00006825View on ClinicalTrials.gov

Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2000

Primary Completion Date

July 31, 2004

Conditions
Breast Cancer
Interventions
BIOLOGICAL

trastuzumab

DRUG

pegylated liposomal doxorubicin hydrochloride

Trial Locations (1)

10016

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

NYU Langone Health

OTHER

NCT00006825 - Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer | Biotech Hunter | Biotech Hunter